A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs BG 00011 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms SPIRIT
- Sponsors Biogen
- 17 Sep 2018 Status changed from not yet recruiting to recruiting.
- 19 Jun 2018 Status changed from planning to not yet recruiting.
- 26 Oct 2017 New trial record